460 related articles for article (PubMed ID: 25622626)
1. [Early conversion from calcineurin inhibitor to sirolimusto after renal transplantation:a prospective, open-label and non-randomized control study].
Huang H; Xie W; Wu J; Xu Y; Yu X; Ren P; Chen J
Zhonghua Yi Xue Za Zhi; 2014 Nov; 94(42):3293-7. PubMed ID: 25622626
[TBL] [Abstract][Full Text] [Related]
2. Conversion from calcineurin inhibitors to sirolimus of recipients with chronic kidney graft disease grade III for a period 2003-2011.
Ignjatović L; Hrvacević R; Jovanović D; Kovacević Z; Vavić N; Rabrenović V; Tomić A; Aleksić P; Drasković-Pavlović B; Dujić A; Karan Z; Maksić D
Vojnosanit Pregl; 2013 Sep; 70(9):848-53. PubMed ID: 24266313
[TBL] [Abstract][Full Text] [Related]
3. Conversion from calcineurin inhibitor to either mycophenolate mofetil or sirolimus improves renal function in liver transplant recipients with chronic kidney disease: results of a prospective randomized trial.
Herlenius G; Felldin M; Nordén G; Olausson M; Bäckman L; Gustafsson B; Friman S
Transplant Proc; 2010 Dec; 42(10):4441-8. PubMed ID: 21168715
[TBL] [Abstract][Full Text] [Related]
4. Calcineurin inhibitor-free mycophenolate mofetil/sirolimus maintenance in liver transplantation: the randomized spare-the-nephron trial.
Teperman L; Moonka D; Sebastian A; Sher L; Marotta P; Marsh C; Koneru B; Goss J; Preston D; Roberts JP;
Liver Transpl; 2013 Jul; 19(7):675-89. PubMed ID: 23775875
[TBL] [Abstract][Full Text] [Related]
5. [Effectiveness and safety of conversion therapy with the combination of sirolimus with low dose cyclosporine in renal transplantation recipients: a five-year clinical observation].
Zhu L; Ding T; Wang XX; Lin ZB; Chen G
Zhonghua Yi Xue Za Zhi; 2016 May; 96(20):1556-61. PubMed ID: 27266681
[TBL] [Abstract][Full Text] [Related]
6. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
[TBL] [Abstract][Full Text] [Related]
7. Effect of early conversion from CNI to sirolimus on outcomes in kidney transplant recipients with allograft dysfunction.
Paoletti E; Ratto E; Bellino D; Marsano L; Cassottana P; Cannella G
J Nephrol; 2012; 25(5):709-18. PubMed ID: 22038336
[TBL] [Abstract][Full Text] [Related]
8. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.
Tsai MK; Wu FL; Lai IR; Lee CY; Hu RH; Lee PH
Int J Artif Organs; 2009 Jun; 32(6):371-80. PubMed ID: 19670189
[TBL] [Abstract][Full Text] [Related]
9. Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: one-year analysis of a randomized multicenter trial.
Guba M; Pratschke J; Hugo C; Krämer BK; Nohr-Westphal C; Brockmann J; Andrassy J; Reinke P; Pressmar K; Hakenberg O; Fischereder M; Pascher A; Illner WD; Banas B; Jauch KW;
Transplantation; 2010 Jul; 90(2):175-83. PubMed ID: 20463641
[TBL] [Abstract][Full Text] [Related]
10. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients.
Raichlin E; Khalpey Z; Kremers W; Frantz RP; Rodeheffer RJ; Clavell AL; Edwards BS; Kushwaha SS
Transplantation; 2007 Aug; 84(4):467-74. PubMed ID: 17713429
[TBL] [Abstract][Full Text] [Related]
11. Outcomes with conversion from calcineurin inhibitors to sirolimus after renal transplantation in the context of steroid withdrawal or steroid continuation.
Egbuna OI; Davis RB; Chudinski R; Pavlakis M; Rogers C; Molakatalla P; Johnson SR; Karp S; Monaco AP; Tang H; Hanto DW; Mandelbrot DA
Transplantation; 2009 Sep; 88(5):684-92. PubMed ID: 19741466
[TBL] [Abstract][Full Text] [Related]
12. SRL-based immunosuppression vs. CNI minimization in pediatric renal transplant recipients with chronic CNI nephrotoxicity.
Höcker B; Feneberg R; Köpf S; Weber LT; Waldherr R; Wühl E; Tönshoff B
Pediatr Transplant; 2006 Aug; 10(5):593-601. PubMed ID: 16856996
[TBL] [Abstract][Full Text] [Related]
13. Influence of sirolimus on proteinuria in de novo kidney transplantation with expanded criteria donors: comparison of two CNI-free protocols.
Diekmann F; Gutiérrez-Dalmau A; López S; Cofán F; Esforzado N; Ricart MJ; Rossich E; Saval N; Torregrosa JV; Oppenheimer F; Campistol JM
Nephrol Dial Transplant; 2007 Aug; 22(8):2316-21. PubMed ID: 17452413
[TBL] [Abstract][Full Text] [Related]
14. High incidence of rejection episodes and poor tolerance of sirolimus in a protocol with early steroid withdrawal and calcineurin inhibitor-free maintenance therapy in renal transplantation: experiences of a randomized prospective single-center study.
Burkhalter F; Oettl T; Descoeudres B; Bachmann A; Guerke L; Mihatsch MJ; Dickenmann M; Steiger J
Transplant Proc; 2012 Dec; 44(10):2961-5. PubMed ID: 23195006
[TBL] [Abstract][Full Text] [Related]
15. Mycophenolate and sirolimus as calcineurin inhibitor-free immunosuppression improves renal function better than calcineurin inhibitor-reduction in late cardiac transplant recipients with chronic renal failure.
Groetzner J; Kaczmarek I; Schulz U; Stegemann E; Kaiser K; Wittwer T; Schirmer J; Voss M; Strauch J; Wahlers T; Sohn HY; Wagner F; Tenderich G; Stempfle HU; Mueller-Ehmsen J; Schmid C; Vogeser M; Koch KC; Reichenspurner H; Daebritz S; Meiser B; Reichart B;
Transplantation; 2009 Mar; 87(5):726-33. PubMed ID: 19295318
[TBL] [Abstract][Full Text] [Related]
16. Renal recovery after conversion to a calcineurin inhibitor-free immunosuppression in late cardiac transplant recipients.
Groetzner J; Kaczmarek I; Landwehr P; Mueller M; Daebritz S; Lamm P; Meiser B; Reichart B
Eur J Cardiothorac Surg; 2004 Mar; 25(3):333-41. PubMed ID: 15019657
[TBL] [Abstract][Full Text] [Related]
17. Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial.
Weir MR; Mulgaonkar S; Chan L; Shidban H; Waid TH; Preston D; Kalil RN; Pearson TC
Kidney Int; 2011 Apr; 79(8):897-907. PubMed ID: 21191361
[TBL] [Abstract][Full Text] [Related]
18. Conversion to combined therapy with sirolimus and mycophenolate mofetil improved renal function in stable renal transplant recipients.
Tsai MK; Lee CY; Hu RH; Lee PH
J Formos Med Assoc; 2007 May; 106(5):372-9. PubMed ID: 17561472
[TBL] [Abstract][Full Text] [Related]
19. Early conversion to a sirolimus-based, calcineurin-inhibitor-free immunosuppression in the SMART trial: observational results at 24 and 36months after transplantation.
Guba M; Pratschke J; Hugo C; Krämer BK; Pascher A; Pressmar K; Hakenberg O; Fischereder M; Brockmann J; Andrassy J; Banas B; Jauch KW;
Transpl Int; 2012 Apr; 25(4):416-23. PubMed ID: 22320241
[TBL] [Abstract][Full Text] [Related]
20. Long-term follow-up of 100 high-risk renal transplant recipients converted from calcineurin inhibitors to sirolimus: a single center experience.
Halim MA; Al-Otaibi T; Johny KV; Hamid MH; Tawab KA; Balaha MA; Abraham M; Said T; Nair MP; Al-Waheeb S; Al-Muzairai I; Nampoory MR
Transplant Proc; 2009 Jun; 41(5):1666-70. PubMed ID: 19545704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
